FDBusiness.com

Strong Growth in Global Performance Nutrition Drives Glanbia

 Breaking News
  • Lactalis Expands in Infant Nutrition With €740 Million Acquisition Lactalis Group, the international dairy group based in Laval, France, is acquiring the Nutritional business of Aspen Pharmacare for €739.8 million (R12.9 billion). The business being acquired supplies a wide range of infant nutritional and growing-up milk products across both the premium and value segments. It manufactures and markets well established quality brands, including S-26, [...]...
  • Thatchers Cider to Invest £14 Million in New Cider Mill Thatchers Cider, the family owned English cider producer, is to invest £14 million in a new cider mill at its Myrtle Farm site in Somerset to meet growing demand for its products. The company has applied for planning permission and, if granted, the new mill would come on stream in 2019. “This investment is about our [...]...
  • Coca-Cola Great Britain Teams Up With Premier League Premier League and Coca-Cola Great Britain have announced a new three-and-a-half-year partnership, starting in January 2019. It is the first sponsorship Coca-Cola Great Britain will activate across multiple brands within its portfolio, showcasing a range of drinks including sparkling soft drinks, water and fruit-based drinks, with low and no-sugar options. The partnership will see Coca-Cola work [...]...
  • Barry Callebaut Completes $30 Million Capacity Expansion in North America Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa products, has announced the completion of several expansion investments in three of its North American facilities located in St Hyacinthe, Quebec; Chatham, Ontario; and St Albans, Vermont. The investments amount to close to US$30 million and are in line with previously announced plans. Recent investments [...]...
  • Strong First Half From Hilton Food Group Hilton Food Group, the UK-based leading specialist international food packing business, has reported a 25.0% increase in turnover to £863.6 million and by 24.5% on a constant currency basis for the 28 weeks to 15 July 2018. Volumes increased by 12.7% reflecting growth in the UK, Ireland and Australia. Operating profit for the first half [...]...

Strong Growth in Global Performance Nutrition Drives Glanbia

Strong Growth in Global Performance Nutrition Drives Glanbia
March 13
12:56 2014

Driven by its two growth platforms, Global Performance Nutrition and Global Ingredients, Irish dairy group Glanbia has delivered a good operating and financial performance for 2013. Total group revenues increased by 8% (10.5% constant currency) to €3.3 billion. Total group EBITA at €226.7 million was up 5.6% (9.2% constant currency). Total group EBITA margin was 6.9%, reflecting a 7.9% margin in Glanbia’s wholly owned businesses – down 10 basis points – and 4.3% in joint ventures and associates – down 30 basis points. Adjusted earnings per share was 55.46 cents, up 8.0%. This equates to 11.9% growth on a constant currency basis, ahead of our previously issued guidance.

The results were underpinned by a strong performance by Global Performance Nutrition as branded revenue growth drove a 100 basis point margin expansion and an EBITA increase of 27.9% on a constant currency basis. The Global Ingredients business increased revenues on a constant currency basis by 11.5% and EBITA increased 8.1% while margins were down by 30 basis points. Dairy Ireland’s results declined significantly due to the performance of Consumer Products while Joint Ventures & Associates delivered a positive performance overall.

Glanbia continued to invest significantly in the business over the course of 2013 with total capital expenditure of €112 million. The key projects undertaken in 2013 include capacity expansion in Global Performance Nutrition, Ingredient Technologies’ new state-of-the-art specialty grain processing facility in South Dakota and the new Cheese Innovation Centre in US Cheese. The return on capital employed achieved by the Group in 2013 increased by 10 basis points to 14.2%, a good result in the context of a substantial ongoing capital investment programme.

Siobhan Talbot, group managing director of Glanbia.

The acquisition of Nutramino Holding, a leading Scandinavian sports nutrition business with operations in Denmark, Sweden and Norway, in January 2014 is aligned with the growth strategy of Global Performance Nutrition. Nutramino focuses primarily on branded, ready-to-consume products sold through the gym and convenience channels. The acquisition gives Glanbia a strong foothold in the Scandinavian market and offers the potential to leverage Nutramino capability in the convenience sector in other markets. The business was acquired for a total consideration of approximately €25.5 million.

Siobhan Talbot, group managing director of Glanbia, says: “Our two global growth platforms performed well, particularly Global Performance Nutrition where strong momentum in branded revenue growth and international expansion delivered a 28% increase in profitability, on a constant currency basis. We expect 2014 to be another positive year for the group. We will benefit from our ongoing organic investment programme, good prospects for Global Ingredients and Global Performance Nutrition and an expected improvement in Dairy Ireland.”

She adds: “We are guiding 8% to 10% growth in adjusted earnings per share for the full year 2014, on a constant currency basis. Our ambition is to continue to deliver a similar annual organic growth rate through to 2018, while seeking to sustain a return on capital employed in excess of 12%.”

About Author

mike

mike

Related Articles



Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • September 25, 2018PPMA Show 2018
  • September 27, 2018Int'l Fruit Show (eurofruit)
  • September 30, 2018Trade Fair for Butchers, Caterers and Meat Industry (Meat Expo)
  • October 1, 2018Poznan International Fair
AEC v1.0.4

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber





Subscribe Here



Advertisements